A Phase 2, single-masked, multicentre study to evaluate the safety and efficacy of 2 dose levels of THR-317 for the treatment of diabetic macular oedema (DME)

Trial Profile

A Phase 2, single-masked, multicentre study to evaluate the safety and efficacy of 2 dose levels of THR-317 for the treatment of diabetic macular oedema (DME)

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2018

At a glance

  • Drugs THR 317 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions
  • Sponsors ThromboGenics
  • Most Recent Events

    • 16 Apr 2018 Status changed from active, no longer recruiting to completed.
    • 04 Apr 2018 Results published in the ThromboGenics media release.
    • 04 Apr 2018 According to a ThromboGenics media release, data for the anti-VEGF treatment naive group (n=40) up to Day 90 will be presented at an upcoming ophthalmology meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top